Despite setbacks in Montreal, Nuvama continues to recommend buying shares in Jubilant Pharmova due to a positive outlook, with a specified target price suggested for the company's stock.

Jubilant Generics, a subsidiary of Jubilant Pharmova, has been served a Rs. 107.9 crore tax order. However, the company intends to contest it and anticipates minimal financial repercussions due to the appeal process.

Jubilant Pharmova reports a decrease in Q4 net profit, falling to ₹1.2 billion compared to ₹1.5 billion last year, indicating a decline in earnings for the quarter.

Jubilant Pharmova anticipates an increase in earnings before interest, tax, depreciation, and amortization (EBITDA) margins from the second half of their fiscal year 2027, due to Montreal's production stabilizing. This improvement is intended to offset higher depreciation costs and foster stronger net profit growth.

Jubilant Pharmova's Q4 net profit dropped by 23% compared to last year, landing at ₹119 crore, but revenue showed a more positive trend, increasing by 19% to reach ₹2,290 crore. However, earnings before interest, taxes, depreciation, and amortization (EBITDA) saw a minor decline of 1.6%, and profit margins narrowed from 17.9% to 14.8%.

Jubilant Pharmova's current CFO is stepping down on May 22, 2026, and will be replaced by Ashish Mukkirwar starting from May 23, 2026. The outgoing CFO will continue to advise the chairmen in a new role post-resignation.